-+ 0.00%
-+ 0.00%
-+ 0.00%

Iambic Therapeutics Director Evan Lockwood Rachlin Reports $11.5 Million Common Share Acquisition

PUBT·10/19/2026 23:48:19
Listen to the news
Iambic Therapeutics Director Evan Lockwood Rachlin Reports $11.5 Million Common Share Acquisition
  • Iambic Therapeutics director Evan Lockwood Rachlin reported an indirect purchase of 718,750 common shares at $16 per share.
  • Conversions of preferred stock and Convertible Promissory Notes added 1,927,252 common shares, bringing his reported indirect holdings to 2,646,002 shares.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iambic Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0002151678-26-000007), on October 19, 2026, and is solely responsible for the information contained therein.